Denver based Ceragenix Pharmaceuticals (NASDAQ: CGXP.OB), led in part by the research of Chief Scientific Officer Dr. Peter Elias, (UCSF), today was awarded a $1.2M NIH grant to examine the skins barrier function as it relates to eczema vaccinatum, a potentially fatal complication of smallpox vaccination in persons who have or have had eczema. In [...]